The Influence of Immunohistochemical Factors of Bone Marrow Micrometastases on Lung Cancer Patient Survival Rate After Surgical Treatment

• Authors: Maciej Dancewicz , Janusz Kowalewski , Mariusz Bella , Jan Sir
• Languages of publication: EN

Abstracts

EN

The detection of micrometastases in patients with operable non-small cell lung carcinoma (NSCLC) could have a considerable influence on the choice of a proper treatment.The aim of the study was to evaluate the usefulness of microscopic examination and immunohistochemistry for the detection of micrometastases or single malignant cells in the bone marrow of patients undergoing surgery for NSCLC, as their late survival and recurrence-free time is dependent on immunohistochemical markers of cancer metastases in the bone marrow.Material and methods. Thirty-five patients were included in the study. Their age range was from 47 to 78 years old. Bone marrow was obtained from a rib during surgery for lung cancer. Both a resected tumour and bone marrow sample were tested for the presence of cytokeratins AE1/AE3, CAM 5.2, CK-7, and CK-18 and other indicators such as CD31 and CD34. The mean time of observation was 871.6 days.Results. Microscopic examination detected no malignant cells or micrometastases in the bone marrow in the analyzed group. Cytokeratin CAM 5.2 was detected in 33 cases (94.23%) in a lung tumour and in 21 cases (60%) in the bone marrow. Statistical analysis (chi2 NW), showed a statistically significant relationship between the presence of CAM 5.2 expression in a tumour and in the bone marrow. In all analysed cases, the expression of cytokeratin AE1/AE2 was found in a tumour, but was not detected in any bone marrow sample. Cytokeratin CK-7 and CK-18 were present in a tumour in 20 (57.14%) and 23 (65.71%) patients, respectively. In the bone marrow, the expression of cytokeratin CK-7 was found in one case (2.86%), and CK-18 was not found in any patients. Thirteen (37.14%) patients died during follow-up. Local recurrence was diagnosed in three patients (8.57%) and distant metastases in 15 patients (42.86%). Mean recurrence-free time was 687.7 days.Conclusions. On the basis of immunohistological tests, it was shown that a significant correlation existed between the presence of cytokeratin CAM 5.2 expression in a tumour and in the bone marrow. Its presence in the bone marrow was a good predictive factor for recurrence-free time. Mortality and the frequency of locoregional recurrence and distant metastases depend on pathological lung cancer staging.

Keywords

EN

lung cancer; micrometastases; immunohistochemistry; bone marrow; long-term survival

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2007
• Volume: 79
• Issue: 12
• Pages: 741-745

Dates

published

1 - 12 - 2007

online

11 - 2 - 2008

Contributors

author

Maciej Dancewicz

• Department and Clinic of Thoracic Surgery and Tumors, L. Rydygier Collegium Medicum, Bydgoszcz

author

Janusz Kowalewski

• Department and Clinic of Thoracic Surgery and Tumors, L. Rydygier Collegium Medicum, Bydgoszcz

author

Mariusz Bella

• Department and Clinic of Thoracic Surgery and Tumors, L. Rydygier Collegium Medicum, Bydgoszcz

author

Jan Sir

• Department of Patomorphology, Centre of Oncology, Bydgoszcz

References

• Passlick B, Kubuschok B, Izbicki JR et al.: Isolated tumor cells in bone marrow predict reduced survival in lymph node-negative non-small cell lung cancer. Ann Thorac Surg 1999; 68: 2053-58.[PubMed][Crossref]
• Passlick B: Micrometastases in non-small cell lung cancer (NSCLC). Lung Cancer 2001; 34 Suppl 3: 25-29.[Crossref]
• Osaki T, Oyama T, Gu C-D et al.: Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small cell lung cancer. J Clinic Oncol 2002; 20: 2930-36.[Crossref]
• Passlick B, Sienel W, Seen-Hibler R et al.: The 17-1A antigen is expressed on primary, metastatic and disseminated non-small cell lung carcinoma cells. Int J Cancer 2000; 87: 548-52.[Crossref]
• Cote RJ, Hawes D, Chaiwun B et al.: Detection of occult metastases in lung carcinomas: Progress and Implications for lung cancer staging. J Surg Oncol 1998; 69: 265-74.[Crossref][PubMed]
• Pantel K, Izbicki JR, Angstwurm M et al.: Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Research 1993; 53: 1027-31.[WoS][PubMed]
• Passlick B, Pantel K, Kubuschok B et al.: Simultaneous immunocyto-chemical detection of tumor cells in lymph nodes and in bone marrow of patients with respectable bronchial carcinomas. Langenbecks Arch Chir Suppl Kongressbd 1998; 115(Supl I): 21-24.
• Muller P, Schlimok G: Bone marrow "micrometastases" of epithelial tumors: detection and clinical relevance. J Cancer Res Clin Oncol 2000; 126(11): 607-18.[Crossref][PubMed]
• Hermanek P, Hutter RVP, Sobin LH et al.: Classification of Isolated Tumor Cells and Micrometastasis. Cancer 1999; 86(12): 2668-73.[PubMed][Crossref]
• Mattioli S, D'Ovidio F, Tazzari P et al.: Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer. Eur J Cardio-thoracic Surg 2001; 19(4): 576-79.
• Chen YH, Gao W, Zhou T et al.: Detection of bone marrow micrometastasis. Hybridoma 1999; 18(5): 465-66.[PubMed][Crossref]
• Jiao X, Krasna MJ: Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002; 74: 278-84.[Crossref][PubMed]
• Hsu-CP SL, Chen CY, Kwang PC et al.: Bone marrow microinvolvement in non-small cell lung cancer is not a reliable indicator of tumour recurrence and prognosis. Eur J Surg Oncol 2000; 26(7): 691-95.[Crossref]
• Carney DN: Immunohistology of lung cancer. Est J Cancer Clin Oncol 1989; 25: 9-11.[Crossref]

Identifiers

DOI

10.2478/v10035-007-0115-6